Allergan plc (AGN) Position Reduced by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lowered its position in Allergan plc (NYSE:AGN) by 65.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 529 shares of the company’s stock after selling 989 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Allergan were worth $101,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Vantage Investment Partners LLC increased its holdings in Allergan by 3.9% in the third quarter. Vantage Investment Partners LLC now owns 64,500 shares of the company’s stock valued at $12,285,000 after buying an additional 2,400 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its holdings in Allergan by 20.0% in the third quarter. Robeco Institutional Asset Management B.V. now owns 409,554 shares of the company’s stock valued at $78,010,000 after buying an additional 68,154 shares in the last quarter. Pinnacle Financial Partners Inc. increased its holdings in Allergan by 8.5% in the third quarter. Pinnacle Financial Partners Inc. now owns 22,231 shares of the company’s stock valued at $4,235,000 after buying an additional 1,749 shares in the last quarter. Hikari Power Ltd increased its holdings in Allergan by 31.6% in the third quarter. Hikari Power Ltd now owns 153,580 shares of the company’s stock valued at $29,254,000 after buying an additional 36,850 shares in the last quarter. Finally, Arvest Bank Trust Division increased its holdings in Allergan by 13.8% in the third quarter. Arvest Bank Trust Division now owns 63,296 shares of the company’s stock valued at $12,057,000 after buying an additional 7,666 shares in the last quarter. Hedge funds and other institutional investors own 77.58% of the company’s stock.

A number of research analysts have issued reports on the stock. Zacks Investment Research cut shares of Allergan from a “hold” rating to a “sell” rating in a report on Wednesday, October 3rd. ValuEngine raised shares of Allergan from a “strong sell” rating to a “sell” rating in a report on Friday, September 21st. TheStreet raised shares of Allergan from a “d+” rating to a “c” rating in a report on Monday, August 20th. Cowen set a $255.00 target price on shares of Allergan and gave the company a “buy” rating in a report on Wednesday, October 17th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and issued a $180.00 target price on shares of Allergan in a report on Friday, September 14th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and eighteen have given a buy rating to the company. Allergan has a consensus rating of “Buy” and a consensus target price of $210.18.

Shares of AGN opened at $163.05 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.21 and a quick ratio of 0.85. Allergan plc has a 1-year low of $142.81 and a 1-year high of $197.00. The company has a market cap of $53.64 billion, a PE ratio of 9.15, a price-to-earnings-growth ratio of 1.27 and a beta of 1.30.

Allergan (NYSE:AGN) last issued its quarterly earnings data on Tuesday, October 30th. The company reported $4.25 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.04 by $0.21. Allergan had a net margin of 14.50% and a return on equity of 8.44%. The business had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.89 billion. During the same period last year, the company posted $4.15 EPS. The company’s revenue was down 3.0% on a year-over-year basis. As a group, sell-side analysts expect that Allergan plc will post 16.42 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 14th. Stockholders of record on Tuesday, November 13th will be paid a dividend of $0.72 per share. The ex-dividend date is Friday, November 9th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.77%. Allergan’s dividend payout ratio (DPR) is 17.61%.

In other Allergan news, Director Christopher J. Coughlin acquired 10,000 shares of the company’s stock in a transaction dated Thursday, September 6th. The stock was acquired at an average cost of $190.64 per share, with a total value of $1,906,400.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Joseph H. Boccuzi acquired 900 shares of the company’s stock in a transaction dated Thursday, August 30th. The shares were acquired at an average cost of $190.59 per share, with a total value of $171,531.00. The disclosure for this purchase can be found here. Company insiders own 0.36% of the company’s stock.

About Allergan

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

See Also: How Short Selling Works

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply